Johnson & Johnson ROE 2012-2025 | JNJ
Current and historical return on equity (ROE) values for Johnson & Johnson (JNJ) over the last 10 years. Return on equity can be defined as the amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested.
| Johnson & Johnson ROE - Return on Equity Historical Data | |||
|---|---|---|---|
| Date | TTM Net Income | Shareholder's Equity | Return on Equity |
| 2025-12-31 | $26.80B | $81.54B | 33.78% |
| 2025-09-30 | $25.12B | $79.28B | 32.69% |
| 2025-06-30 | $22.66B | $78.47B | 30.39% |
| 2025-03-31 | $21.81B | $78.11B | 29.95% |
| 2024-12-31 | $14.07B | $71.49B | 19.87% |
| 2024-09-30 | $14.68B | $70.16B | 20.94% |
| 2024-06-30 | $38.02B | $71.54B | 54.01% |
| 2024-03-31 | $38.48B | $70.02B | 53.73% |
| 2023-12-31 | $35.15B | $68.77B | 48.95% |
| 2023-09-30 | $34.62B | $71.23B | 46.90% |
| 2023-06-30 | $13.05B | $76.41B | 17.48% |
| 2023-03-31 | $12.72B | $70.87B | 17.04% |
| 2022-12-31 | $17.94B | $76.80B | 23.73% |
| 2022-09-30 | $19.16B | $74.60B | 25.57% |
| 2022-06-30 | $18.37B | $76.36B | 24.87% |
| 2022-03-31 | $19.83B | $74.71B | 27.49% |
| 2021-12-31 | $20.88B | $74.02B | 29.86% |
| 2021-09-30 | $17.88B | $70.27B | 26.59% |
| 2021-06-30 | $17.77B | $69.58B | 27.01% |
| 2021-03-31 | $15.12B | $65.83B | 23.57% |
| 2020-12-31 | $14.71B | $63.28B | 23.35% |
| 2020-09-30 | $16.99B | $64.47B | 27.37% |
| 2020-06-30 | $15.19B | $62.98B | 25.10% |
| 2020-03-31 | $17.17B | $61.29B | 28.64% |
| 2019-12-31 | $15.12B | $59.47B | 25.47% |
| 2019-09-30 | $14.15B | $58.21B | 23.81% |
| 2019-06-30 | $16.33B | $60.79B | 26.76% |
| 2019-03-31 | $14.68B | $58.96B | 23.85% |
| 2018-12-31 | $15.30B | $59.75B | 24.42% |
| 2018-09-30 | $1.54B | $64.63B | 2.46% |
| 2018-06-30 | $1.37B | $62.89B | 2.11% |
| 2018-03-31 | $1.25B | $63.26B | 1.85% |
| 2017-12-31 | $1.30B | $60.16B | 1.88% |
| 2017-09-30 | $15.83B | $73.98B | 22.08% |
| 2017-06-30 | $16.34B | $71.92B | 22.89% |
| 2017-03-31 | $16.51B | $70.34B | 23.08% |
| 2016-12-31 | $16.54B | $70.42B | 22.95% |
| 2016-09-30 | $15.94B | $72.77B | 22.06% |
| 2016-06-30 | $15.03B | $72.47B | 20.88% |
| 2016-03-31 | $15.55B | $72.65B | 21.71% |
| 2015-12-31 | $15.41B | $71.15B | 21.88% |
| 2015-09-30 | $14.72B | $71.55B | 21.00% |
| 2015-06-30 | $16.11B | $71.13B | 22.58% |
| 2015-03-31 | $15.92B | $67.88B | 21.78% |
| 2014-12-31 | $16.32B | $69.75B | 21.69% |
| 2014-09-30 | $17.32B | $76.59B | 22.70% |
| 2014-06-30 | $15.55B | $78.05B | 20.84% |
| 2014-03-31 | $15.06B | $76.58B | 20.77% |
| 2013-12-31 | $13.83B | $74.05B | 19.73% |
| 2013-09-30 | $12.88B | $69.80B | 19.00% |
| 2013-06-30 | $12.87B | $69.67B | 19.41% |
| 2013-03-31 | $10.44B | $66.86B | 16.32% |
| 2012-12-31 | $10.85B | $64.83B | 17.34% |
| 2012-09-30 | $8.50B | $63.76B | 14.02% |
| 2012-06-30 | $8.74B | $60.43B | 14.54% |
| 2012-03-31 | $10.11B | $61.37B | 16.70% |
| 2011-12-31 | $9.67B | $57.08B | 16.08% |
| 2011-09-30 | $11.40B | $61.53B | 18.99% |
| 2011-06-30 | $11.61B | $62.13B | 19.69% |
| 2011-03-31 | $12.28B | $59.86B | 21.69% |
| 2010-12-31 | $13.33B | $56.58B | 24.28% |
| 2010-09-30 | $13.60B | $57.29B | 25.46% |
| 2010-06-30 | $13.53B | $52.85B | 26.17% |
| 2010-03-31 | $13.29B | $52.91B | 26.55% |
| 2009-12-31 | $12.27B | $50.59B | 25.69% |
| 2009-09-30 | $12.77B | $50.38B | 27.93% |
| 2009-06-30 | $12.74B | $46.25B | 28.58% |
| 2009-03-31 | $12.86B | $43.79B | 28.82% |
| 2008-12-31 | $12.95B | $42.51B | 28.73% |
| 2008-09-30 | $12.61B | $45.73B | 27.85% |
| 2008-06-30 | $11.85B | $46.44B | 26.48% |
| 2008-03-31 | $11.60B | $45.63B | 26.42% |
| 2007-12-31 | $10.58B | $43.32B | 24.75% |
| 2007-09-30 | $10.37B | $43.57B | 24.85% |
| 2007-06-30 | $10.58B | $43.12B | 25.82% |
| 2007-03-31 | $10.32B | $40.93B | 25.55% |
| 2006-12-31 | $11.05B | $39.32B | 27.33% |
| 2006-09-30 | $10.98B | $40.57B | 27.25% |
| 2006-06-30 | $10.76B | $40.74B | 27.34% |
| 2006-03-31 | $10.53B | $41.12B | 27.73% |
| 2005-12-31 | $10.06B | $38.71B | 27.87% |
| 2005-09-30 | $8.85B | $36.85B | 25.76% |
| 2005-06-30 | $8.66B | $35.17B | 26.20% |
| 2005-03-31 | $8.53B | $33.65B | 26.85% |
| 2004-12-31 | $8.18B | $31.81B | 26.85% |
| 2004-09-30 | $9.14B | $31.51B | 31.26% |
| 2004-06-30 | $8.87B | $30.05B | 31.91% |
| 2004-03-31 | $7.62B | $28.49B | 28.88% |
| 2003-12-31 | $7.20B | $26.87B | 28.48% |
| 2003-09-30 | $6.74B | $25.74B | 27.80% |
| 2003-06-30 | $6.39B | $24.44B | 27.40% |
| 2003-03-31 | $6.83B | $24.04B | 30.13% |
| 2002-12-31 | $6.60B | $22.70B | 29.19% |
| 2002-09-30 | $6.32B | $22.09B | 27.49% |
| 2002-06-30 | $6.12B | $21.89B | 26.17% |
| 2002-03-31 | $5.95B | $23.72B | 25.21% |
| 2001-12-31 | $5.67B | $24.23B | 24.98% |
| 2001-09-30 | $5.45B | $23.73B | 25.10% |
| 2001-06-30 | $5.25B | $22.71B | 25.70% |
| 2001-03-31 | $5.13B | $20.09B | 26.66% |
| 2000-12-31 | $4.89B | $20.40B | 26.43% |
| 2000-09-30 | $4.75B | $18.49B | 27.23% |
| 2000-06-30 | $4.54B | $17.98B | 27.23% |
| 2000-03-31 | $4.34B | $17.15B | 27.36% |
| 1999-12-31 | $4.17B | $16.21B | 27.52% |
| 1999-09-30 | $3.52B | $15.38B | 24.27% |
| 1999-06-30 | $3.37B | $14.74B | 23.85% |
| 1999-03-31 | $3.22B | $14.22B | 23.41% |
| 1998-12-31 | $3.00B | $13.59B | 22.39% |
| 1998-09-30 | $3.53B | $13.94B | 26.95% |
| 1998-06-30 | $3.42B | $13.31B | 27.02% |
| 1998-03-31 | $3.31B | $12.81B | 27.01% |
| 1997-12-31 | $3.30B | $12.36B | 27.85% |
| 1997-09-30 | $3.23B | $12.18B | 28.13% |
| 1997-06-30 | $3.12B | $11.72B | 28.14% |
| 1997-03-31 | $3.01B | $11.17B | 28.01% |
| 1996-12-31 | $2.89B | $10.84B | 27.77% |
| 1996-09-30 | $2.80B | $10.68B | 28.11% |
| 1996-06-30 | $2.67B | $10.24B | 28.08% |
| 1996-03-31 | $2.54B | $9.83B | 27.94% |
| 1995-12-31 | $2.40B | $9.05B | 27.94% |
| 1995-09-30 | $2.32B | $8.91B | 28.52% |
| 1995-06-30 | $2.22B | $8.56B | 29.03% |
| 1995-03-31 | $2.12B | $7.88B | 29.58% |
| 1994-12-31 | $2.01B | $7.12B | 29.91% |
| 1994-09-30 | $1.96B | $6.99B | 31.07% |
| 1994-06-30 | $1.89B | $6.62B | 31.56% |
| 1994-03-31 | $1.83B | $6.09B | 31.71% |
| 1993-12-31 | $1.79B | $5.57B | 31.75% |
| 1993-09-30 | $1.76B | $5.70B | 31.82% |
| 1993-06-30 | $1.72B | $5.71B | 30.71% |
| 1993-03-31 | $1.68B | $5.54B | 29.93% |
| 1992-12-31 | $1.65B | $5.17B | 29.19% |
| 1992-09-30 | $1.62B | $5.97B | 28.05% |
| 1992-06-30 | $1.57B | $5.71B | 27.91% |
| 1992-03-31 | $1.52B | $5.74B | 27.89% |
| 1991-12-31 | $1.46B | $5.63B | 27.86% |
| 1991-09-30 | $1.42B | $5.36B | 28.03% |
| 1991-06-30 | $1.37B | $5.06B | 27.91% |
| 1991-03-31 | $1.32B | $4.93B | 27.56% |
| 1990-12-31 | $1.14B | $4.90B | 24.75% |
| 1990-09-30 | $1.11B | $4.74B | 25.14% |
| 1990-06-30 | $1.07B | $4.55B | 25.19% |
| 1990-03-31 | $1.01B | $4.29B | 25.04% |
| 1989-12-31 | $1.08B | $4.15B | 28.01% |
| 1989-09-30 | $1.06B | $3.93B | 28.72% |
| 1989-06-30 | $1.04B | $3.75B | 28.87% |
| 1989-03-31 | $1.01B | $3.62B | 28.45% |
| 1988-12-31 | $0.97B | $3.50B | 27.28% |
| 1988-09-30 | $0.95B | $3.51B | 26.73% |
| 1988-06-30 | $0.92B | $3.60B | 26.29% |
| 1988-03-31 | $0.88B | $3.67B | 25.76% |
| 1987-12-31 | $0.83B | $3.49B | 25.72% |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Large Cap Pharmaceutical | $586.690B | $94.193B |
| Johnson & Johnson's biggest strength is its diversified business model. It operates through pharmaceuticals, medical devices and consumer products divisions. Its diversification helps it to withstand economic cycles more effectively. J&J has one of the largest research and development (R&D) budget among pharma companies. J&J's worldwide business is divided into three segments: Pharmaceutical, Medical Devices and Consumer. The company has several drugs covering a broad range of areas such as neuroscience, cardiovascular & metabolism, immunology, oncology, pulmonary hypertension and infectious diseases and vaccines. The Medical Devices Segment offers products in the orthopedics, surgery, interventional solutions and vision markets. The Consumer Segment segment includes a broad range of products covering the areas of baby care, beauty/skin health, oral care, wound care and womens' health care, as well as over-the-counter (OTC) pharmaceutical products. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eli Lilly (LLY) | United States | $981.092B | 42.96 |
| AbbVie (ABBV) | United States | $409.150B | 23.15 |
| Roche Holding AG (RHHBY) | Switzerland | $372.740B | 0.00 |
| Novartis AG (NVS) | Switzerland | $344.536B | 18.16 |
| Merck (MRK) | United States | $301.342B | 13.53 |
| Novo Nordisk (NVO) | Denmark | $221.330B | 12.68 |
| Pfizer (PFE) | United States | $156.812B | 8.54 |
| Sanofi (SNY) | France | $112.219B | 10.39 |
| Bayer (BAYRY) | Germany | $53.369B | 9.37 |
| Innoviva (INVA) | United States | $1.697B | 8.50 |